GO:0097193 intrinsic apoptotic signaling pathway: Mitochondrial Apoptosis, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0097193 intrinsic apoptotic signaling pathway describes the intracellular cascade that senses damage signals such as DNA damage, ER stress, and oxidative stress and triggers apoptotic cell death through mitochondrial outer membrane permeabilization (MOMP).
• The pathway is governed by BCL-2 family proteins: multidomain effectors BAX and BAK execute MOMP, while anti-apoptotic BCL-2, BCL-XL, and MCL-1 restrain them and BH3-only sensors such as BIM, PUMA, and BID initiate activation.
• MOMP releases cytochrome c, which assembles the apoptosome with APAF-1 and caspase-9, activating executioner caspases-3 and -7 that dismantle the cell.
• Defective intrinsic apoptosis contributes to cancer initiation, progression, and therapy resistance, making it a central target for anticancer drug development.
• Excessive intrinsic apoptosis is implicated in neurodegenerative conditions such as Alzheimer's disease, where neuronal loss is linked to mitochondrial apoptotic signaling.
• CRISPR knockout, point-mutation, knock-in, and overexpression cell models enable causal dissection of BCL-2 family and caspase gene function in this pathway.
Description
The intrinsic apoptotic signaling pathway (GO:0097193) is the cell-intrinsic death program that converts diverse intracellular stress signals into a coordinated execution of apoptosis. Unlike the extrinsic pathway, which is triggered by extracellular ligands engaging death receptors, the intrinsic pathway originates inside the cell in response to DNA damage, endoplasmic reticulum stress, oxidative stress, and other insults, and converges on permeabilization of the mitochondrial outer membrane (MOMP). This mitochondrial control point is widely regarded as the decisive event that commits a cell to death. Because apoptosis is essential for tissue homeostasis, development, and immune surveillance, its dysregulation is a hallmark of many human diseases. In cancer, tumor cells frequently evade intrinsic apoptosis by overexpressing anti-apoptotic BCL-2 family proteins or by losing pro-apoptotic effectors, which also underlies resistance to chemotherapy and targeted agents. In neurodegeneration, by contrast, inappropriate activation of the intrinsic pathway contributes to neuronal loss. Understanding the molecular wiring of GO:0097193 therefore has direct translational value for oncology, neurology, and drug discovery. This article summarizes the definition, core mechanisms, key genes, disease links, and experimental strategies used to study the intrinsic apoptotic signaling pathway, based on authoritative QuickGO annotation and published literature.
intrinsic apoptotic signaling pathway At A Glance
| GO ID | GO:0097193 |
|---|---|
| GO term | intrinsic apoptotic signaling pathway |
| Ontology | biological_process |
| Synonyms | induction of apoptosis by intracellular signals; intrinsic apoptosis; intrinsic apoptotic pathway; intrinsic apoptotic signalling pathway; mitochondrial-mediated apoptotic pathway |
| Major function | Transduces intracellular stress signals into mitochondrial outer membrane permeabilization and caspase-dependent apoptotic execution |
| Key organelles | Mitochondria (MOMP, cytochrome c release), cytosol (apoptosome), nucleus (DNA damage sensing) |
| Key protein families | BCL-2 family (BAX, BAK, BID, BIM, PUMA, BCL-2, BCL-XL, MCL-1), caspases (caspase-9, -3, -7), APAF-1 |
| Upstream triggers | DNA damage, ER stress, oxidative stress, growth factor withdrawal, oncogenic stress |
| Downstream outcome | Apoptosome formation, caspase activation, substrate cleavage, cell death |
What Is GO:0097193?
GO:0097193 intrinsic apoptotic signaling pathway is defined as the series of molecular signals in which an intracellular signal is conveyed to trigger the apoptotic death of a cell. The pathway begins with reception of an intracellular signal such as DNA damage, endoplasmic reticulum stress, or oxidative stress, and ends when the execution phase of apoptosis is triggered. It is crucially regulated by permeabilization of the mitochondrial outer membrane (MOMP), which releases pro-apoptotic factors from the mitochondrial intermembrane space and commits the cell to death.
Why Is intrinsic apoptotic signaling pathway Important in Cell Biology?
The intrinsic apoptotic signaling pathway is a central determinant of cell fate and a major node in human disease. Its evasion is a hallmark of cancer, where overexpression of anti-apoptotic proteins such as BCL-2, BCL-XL, and MCL-1 or loss of effectors like BAX and BAK permits survival of malignant cells and confers resistance to chemotherapy and targeted therapies. Conversely, excessive or inappropriate activation of the pathway contributes to pathological cell loss in neurodegenerative disorders such as Alzheimer's disease. Because MOMP is the point of no return, therapeutic strategies that directly modulate BCL-2 family interactions, including BH3 mimetics, are actively being developed and tested. Studying GO:0097193 therefore informs cancer biology, neurobiology, and the rational design of apoptosis-targeted drugs.
• Evasion of intrinsic apoptosis is a hallmark of cancer and a driver of tumor initiation and progression.
• Anti-apoptotic BCL-2 family proteins mediate resistance to chemotherapy and targeted agents in hematologic and solid tumors.
• BH3 mimetics and other apoptosis-targeting drugs are clinically relevant strategies that act on this pathway.
• Excessive intrinsic apoptosis contributes to neuronal loss in Alzheimer's disease and other neurodegenerative conditions.
• The pathway is essential for normal development, tissue homeostasis, and immune surveillance.
• MOMP is the decisive commitment step and a key mechanistic focus for experimental interrogation.
• Caspase-9 and executioner caspases-3/-7 are core effectors whose activity can be measured experimentally.
• Intrinsic and extrinsic pathways crosstalk through BID cleavage, linking receptor signaling to mitochondrial apoptosis.
• The pathway is frequently dysregulated in acute myeloid leukemia and other hematologic malignancies.
• CRISPR-based models enable causal testing of pathway gene function in disease-relevant cell types.
What Happens During intrinsic apoptotic signaling pathway?
Reception of intracellular stress signals
In simple terms: The pathway starts when the cell senses internal damage, such as broken DNA or stress in its organelles.
The intrinsic apoptotic signaling pathway is initiated by intracellular signals including DNA damage, endoplasmic reticulum stress, oxidative stress, and other cellular insults. These signals are sensed by upstream regulators that transmit the stress information to the BCL-2 family machinery, converting a diverse set of damage inputs into a common death decision. Because the trigger is intracellular rather than a death ligand, this pathway is mechanistically distinct from the extrinsic, receptor-driven route.
BH3-only sensor activation and BCL-2 family integration
In simple terms: Sensor proteins switch on and tip the balance toward cell death by disabling the cell's survival proteins.
BH3-only proteins such as BIM, PUMA, and BID act as stress sensors that are transcriptionally or post-translationally activated following cellular damage. They neutralize anti-apoptotic guardians including BCL-2, BCL-XL, and MCL-1, thereby relieving inhibition of the multidomain effectors BAX and BAK. This integration step determines whether the cell survives or commits to apoptosis, and the balance between pro- and anti-apoptotic BCL-2 family members is a key determinant of the apoptotic threshold.
Mitochondrial outer membrane permeabilization (MOMP)
In simple terms: The mitochondria become leaky, which is the point of no return for the cell.
Activated BAX and BAK undergo conformational change, oligomerize, and permeabilize the mitochondrial outer membrane, a process known as MOMP. MOMP is crucially regulated and represents the decisive commitment step of the intrinsic pathway. It results in the release of intermembrane-space proteins, most notably cytochrome c, into the cytosol.
Apoptosome assembly and caspase-9 activation
In simple terms: Released cytochrome c builds a molecular platform that switches on the first death caspase.
Once in the cytosol, cytochrome c binds APAF-1 and promotes assembly of the apoptosome, a heptameric platform that recruits and activates initiator caspase-9. Active caspase-9 then cleaves and activates downstream executioner caspases, propagating the death signal. This step links mitochondrial permeabilization to the enzymatic execution machinery of apoptosis.
Execution phase and cellular dismantling
In simple terms: Executioner caspases cut up key cellular structures, leading to the controlled death of the cell.
Executioner caspases-3 and -7 cleave a broad set of substrates, producing the morphological hallmarks of apoptosis including chromatin condensation, nuclear fragmentation, and membrane blebbing. The pathway ends when this execution phase is triggered, as specified in the GO definition. The coordinated dismantling of the cell ensures that death occurs without provoking inflammation, in contrast to necrosis.
Key Genes Involved in GO:0097193 intrinsic apoptotic signaling pathway
The intrinsic apoptotic signaling pathway is orchestrated by BCL-2 family proteins, caspases, and adaptor molecules whose functions have been defined through decades of cell and molecular biology research.
| Gene | Major Role | Research Relevance |
|---|---|---|
| BAX | Multidomain pro-apoptotic effector that oligomerizes to permeabilize mitochondria during MOMP | Central effector; knockout models resist apoptosis and are widely used to test pathway dependence |
| BAK | Multidomain pro-apoptotic effector cooperating with BAX in MOMP | Frequently studied alongside BAX; double knockout confers strong apoptotic resistance |
| BCL2 | Anti-apoptotic guardian protein that inhibits BAX/BAK | Overexpression is common in lymphoma and leukemia; target of BH3 mimetics |
| BCL2L1 (BCL-XL) | Anti-apoptotic protein restraining MOMP | Mediates resistance to apoptosis in solid tumors and hematologic malignancies |
| MCL1 | Anti-apoptotic protein that sequesters BH3-only activators | Key resistance factor in acute myeloid leukemia and other cancers |
| BID | BH3-only protein linking extrinsic and intrinsic pathways via caspase-8 cleavage | Used to study crosstalk between death receptor and mitochondrial apoptosis |
| BBC3 (PUMA) | BH3-only sensor induced by p53 after DNA damage | Readout of p53-dependent apoptosis and chemosensitivity |
| BCL2L11 (BIM) | BH3-only sensor activated by growth factor withdrawal and stress | Important for targeted therapy responses and immune homeostasis |
| PMAIP1 (NOXA) | BH3-only protein targeting MCL1 | Modulates apoptotic priming and drug sensitivity |
| APAF1 | Adaptor that forms the apoptosome with cytochrome c and caspase-9 | Essential for caspase-9 activation; knockout blocks mitochondrial apoptosis |
| CASP9 | Initiator caspase activated at the apoptosome | Core effector of the intrinsic pathway; key experimental readout |
| CASP3 | Executioner caspase that dismantles the cell | Activity assays and cleavage products are standard apoptosis markers |
| CASP7 | Executioner caspase cooperating with caspase-3 | Studied for redundancy and substrate specificity in apoptosis |
| TP53 | Transcription factor inducing PUMA, NOXA, and BAX after DNA damage | Master regulator linking genotoxic stress to intrinsic apoptosis |
| CYCS | Cytochrome c released during MOMP to trigger apoptosome assembly | Biomarker of MOMP and mitochondrial apoptosis |
| DIABLO (SMAC) | Mitochondrial protein released during MOMP that antagonizes IAPs | Modulates caspase activity and apoptosis sensitivity |
| XIAP | Inhibitor of apoptosis protein that restrains caspases | Determines apoptotic threshold and resistance phenotypes |
| ENDOG | Endonuclease released from mitochondria that mediates nuclear DNA fragmentation | Marker of apoptotic DNA degradation |
How Is intrinsic apoptotic signaling pathway Regulated?
The intrinsic apoptotic signaling pathway is tightly regulated at multiple levels. Transcriptional control by p53 induces pro-apoptotic BH3-only genes such as PUMA and NOXA and the effector BAX in response to DNA damage. Post-translational regulation includes phosphorylation, ubiquitination, and proteasomal degradation of BCL-2 family proteins, which set the apoptotic threshold. Anti-apoptotic proteins BCL-2, BCL-XL, and MCL-1 act as rheostats that sequester pro-apoptotic counterparts, and their abundance is frequently altered in cancer. Inhibitor of apoptosis proteins (IAPs) such as XIAP provide an additional brake on caspase activity downstream of mitochondria. Growth factor signaling and oncogenic stress also modulate pathway sensitivity, and therapeutic agents including BH3 mimetics and histone deacetylase inhibitors can shift the balance toward apoptosis.
intrinsic apoptotic signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| BCL2 | Lymphoma and leukemia; anti-apoptotic overexpression drives survival | Overexpression and point-mutation knock-in cell models to test BH3 mimetic sensitivity |
| MCL1 | Acute myeloid leukemia resistance to targeted therapy | Knockout and inducible overexpression models in leukemia cell lines |
| BAX | Loss reduces apoptotic response and contributes to tumorigenesis | Knockout cell lines to test pathway dependence |
| TP53 | DNA damage response and chemosensitivity via PUMA/NOXA/BAX induction | Point-mutation knock-in models of p53 mutants |
| CASP3 | Executioner caspase; altered activity affects therapy response | Knockout and activity-reporter models |
Cancer: evasion of intrinsic apoptosis
Cancer cells commonly evade intrinsic apoptosis by overexpressing anti-apoptotic BCL-2 family proteins or by losing pro-apoptotic effectors, which supports tumor survival and resistance to therapy. In acute myeloid leukemia, resistance to targeted therapy is frequently linked to MCL-1 and BCL-2 dependence, motivating combination strategies with BH3 mimetics. Histone deacetylase inhibitors can shift the balance toward intrinsic apoptosis and have been studied as antitumor agents whose activity depends on pathway integrity. Targeting apoptotic pathways is therefore a major therapeutic strategy in oncology.
Neurodegeneration: excessive intrinsic apoptosis
In Alzheimer's disease, aberrant activation of apoptotic signaling contributes to neuronal loss, and the intrinsic pathway is a focus for understanding disease mechanisms and therapeutic avenues. Because neurons are post-mitotic and vulnerable to mitochondrial dysfunction, MOMP-related death signaling is particularly consequential in the nervous system. Modulating BCL-2 family interactions is being explored as a neuroprotective strategy.
Hematologic malignancies and therapy resistance
In acute myeloid leukemia and related hematologic cancers, dysregulated intrinsic apoptosis underlies both disease biology and resistance to targeted agents. Anti-apoptotic proteins such as MCL-1 and BCL-2 are key resistance nodes, and understanding their regulation informs combination regimens. This makes the pathway a central consideration in precision oncology.
Metabolic and stress-related contexts
Metabolic agents such as metformin and its derivatives have been reported to influence tumor-intrinsic pathways, including apoptotic signaling, in breast cancer models. Such findings highlight how cellular stress and metabolic state intersect with the intrinsic apoptotic machinery. These connections broaden the therapeutic relevance of GO:0097193 beyond classical oncology targets.
From intrinsic apoptotic signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a BCL-2 family gene required for MOMP and apoptosis? | CRISPR knockout cell line with apoptotic stimulus challenge |
| Does a cancer-associated mutation alter anti-apoptotic function? | Point-mutation knock-in of the variant allele |
| Can a tagged protein be tracked during apoptosis? | Endogenous tagged knock-in of the gene of interest |
| Does overexpression of an anti-apoptotic gene confer resistance? | Doxycycline-inducible overexpression cell model |
| Which genes modulate sensitivity to BH3 mimetics? | CRISPR library screening in a disease-relevant cell line |
| Is caspase activation required for a death phenotype? | Knockout of CASP3/CASP7 or CASP9 with activity assays |
How to Study the intrinsic apoptotic signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Caspase-3/-7 activity assay | Executioner caspase enzymatic activity | Confirming apoptosis after treatment or gene perturbation |
| Annexin V / flow cytometry | Phosphatidylserine exposure as an apoptosis marker | Quantifying apoptotic cell populations |
| Cytochrome c release assay | MOMP and mitochondrial intermembrane protein release | Testing BAX/BAK-dependent commitment |
| Immunoblotting | Cleavage of caspases and PARP; BCL-2 family levels | Validating pathway activation and protein expression |
| RNA sequencing | Transcriptional changes in apoptotic and stress genes | Identifying pathway regulators and resistance signatures |
| CRISPR knockout screening | Gene requirements for apoptosis or drug sensitivity | Functional genomics of pathway modifiers |
| Live-cell imaging | Mitochondrial dynamics and cell death kinetics | Tracking MOMP and apoptosis in real time |
| BH3 profiling | Mitochondrial priming and dependence on anti-apoptotic proteins | Predicting response to BH3 mimetics |
Apoptosis assays and caspase activity measurement
Caspase-3/-7 activity assays, Annexin V staining, and PARP cleavage immunoblotting are standard methods to quantify intrinsic apoptotic signaling after stimulus. These readouts distinguish apoptosis from other death modalities and are used to validate genetic perturbations.
Mitochondrial function and MOMP analysis
Mitochondrial outer membrane permeabilization can be assessed by cytochrome c release assays, mitochondrial membrane potential dyes, and BAX/BAK conformational change immunostaining. These methods directly interrogate the commitment step of the pathway.
Transcriptomic and proteomic profiling
RNA sequencing and quantitative proteomics reveal changes in BCL-2 family gene expression and stress-response programs following apoptotic stimuli. Such profiling helps identify pathway regulators and resistance mechanisms in disease models.
Genetic perturbation and functional genomics
CRISPR knockout, point-mutation knock-in, and overexpression models combined with viability assays enable causal testing of candidate genes in the pathway. Pooled CRISPR library screens can nominate modifiers of drug-induced apoptosis.
How CRISPR Can Be Used to Study GO:0097193 intrinsic apoptotic signaling pathway
Knockout
CRISPR knockout of BAX, BAK, APAF1, or CASP9 is used to test whether a given apoptotic stimulus requires the intrinsic pathway. Knockout of anti-apoptotic genes such as MCL1 or BCL2 can sensitize cells to death and reveal dependencies relevant to cancer therapy. These models provide causal evidence that complements pharmacological inhibition.
Point Mutation
Point-mutation knock-in can model cancer-associated variants in TP53 or BCL-2 family genes to determine how specific residues alter apoptotic threshold and drug response. Such isogenic models are valuable for linking genotype to apoptotic phenotype.
Knock-in
Tagged knock-in of endogenous BAX, BAK, or cytochrome c enables tracking of protein localization and conformational changes during MOMP. Reporter knock-in lines can also provide sensitive readouts of caspase activation in live cells.
Overexpression
Overexpression of anti-apoptotic BCL-2, BCL-XL, or MCL-1 is widely used to model therapy resistance and to test whether a death phenotype is apoptosis-dependent. Inducible overexpression systems allow controlled titration of apoptotic threshold.
How EDITGENE Supports intrinsic apoptotic signaling pathway Research
Researchers studying intrinsic apoptotic signaling pathway-related genes often need to determine whether a candidate gene is causally involved in setting the apoptotic threshold, executing MOMP, or conferring therapy resistance. Rigorous causal inference requires isogenic cell models in which the gene of interest is deleted, mutated, tagged, or overexpressed in a controlled manner. EDITGENE provides end-to-end CRISPR services tailored to these needs, from knockout and point-mutation models to knock-in reporters, overexpression lines, and functional genomics screens.
Contact EDITGENE today to design your custom CRISPR model for intrinsic apoptotic signaling pathway research.
Frequently Asked Questions About intrinsic apoptotic signaling pathway
What is the intrinsic apoptotic signaling pathway (GO:0097193)?
It is the intracellular signaling cascade that senses damage such as DNA damage, ER stress, and oxidative stress and triggers apoptosis through mitochondrial outer membrane permeabilization (MOMP).
What genes are involved in the intrinsic apoptotic signaling pathway?
Key genes include BAX, BAK, BCL2, BCL2L1 (BCL-XL), MCL1, BID, BBC3 (PUMA), BCL2L11 (BIM), APAF1, CASP9, CASP3, CASP7, TP53, and CYCS.
How does the intrinsic pathway differ from the extrinsic pathway?
The intrinsic pathway is triggered by intracellular stress and converges on mitochondria, whereas the extrinsic pathway is initiated by extracellular death ligands engaging death receptors.
What is MOMP and why is it important?
MOMP is mitochondrial outer membrane permeabilization, the decisive commitment step of the intrinsic pathway that releases cytochrome c and activates caspases.
How is the intrinsic apoptotic pathway regulated?
It is regulated by the balance of pro- and anti-apoptotic BCL-2 family proteins, p53-dependent transcription, post-translational modifications, and inhibitor of apoptosis proteins.
Why is intrinsic apoptosis important in cancer?
Cancer cells evade intrinsic apoptosis by overexpressing anti-apoptotic proteins or losing effectors, which drives tumor survival and therapy resistance.
What diseases are linked to defective intrinsic apoptosis?
Cancer, including leukemia and lymphoma, and neurodegenerative diseases such as Alzheimer's disease are linked to dysregulated intrinsic apoptosis.
How do researchers study the intrinsic apoptotic signaling pathway?
Common methods include caspase activity assays, Annexin V staining, cytochrome c release assays, immunoblotting, RNA sequencing, and CRISPR-based functional genomics.
What are BH3 mimetics?
BH3 mimetics are drugs that mimic BH3-only proteins to inhibit anti-apoptotic BCL-2 family proteins and promote intrinsic apoptosis, and they are used in cancer therapy.
Can CRISPR be used to model intrinsic apoptosis genes?
Yes, CRISPR knockout, point-mutation knock-in, tagged knock-in, and overexpression models are widely used to dissect gene function in this pathway.
Conclusion
The intrinsic apoptotic signaling pathway (GO:0097193) is the mitochondrial death program that converts intracellular stress into caspase-dependent apoptosis, with MOMP as its decisive commitment step. Its core machinery, the BCL-2 family, caspases, and the apoptosome, is well defined and extensively studied in cancer and neurodegeneration. Because dysregulation of this pathway underlies therapy resistance and pathological cell loss, it remains a high-value target for both mechanistic research and drug development. CRISPR-based isogenic models provide the causal evidence needed to translate pathway knowledge into new therapeutic strategies.
References
- 1. Alim R et al.. 2025. Metformin and its derivatives in breast cancer: from glycaemic control to tumor-intrinsic pathways.. Breast Cancer Res 28(1):13 PMID: 41388552
- 2. Mustafa M et al.. 2024. Apoptosis: A Comprehensive Overview of Signaling Pathways, Morphological Changes, and Physiological Significance and Therapeutic Implications.. Cells 13(22) PMID: 39594587
- 3. Tian X et al.. 2024. Targeting apoptotic pathways for cancer therapy.. J Clin Invest 134(14) PMID: 39007268
- 4. Matthews GM et al.. 2012. Intrinsic and extrinsic apoptotic pathway signaling as determinants of histone deacetylase inhibitor antitumor activity.. Adv Cancer Res 116:165-97 PMID: 23088871
- 5. Kiraz Y et al.. 2016. Major apoptotic mechanisms and genes involved in apoptosis.. Tumour Biol 37(7):8471-86 PMID: 27059734
- 6. Kashyap D et al.. 2021. Intrinsic and extrinsic pathways of apoptosis: Role in cancer development and prognosis.. Adv Protein Chem Struct Biol 125:73-120 PMID: 33931145
- 7. Kumari S et al.. 2023. Apoptosis in Alzheimer's disease: insight into the signaling pathways and therapeutic avenues.. Apoptosis 28(7-8):943-957 PMID: 37186274
- 8. Song F et al.. 2025. Targeted therapy in acute myeloid leukemia: Resistance and overcoming strategy.. Drug Resist Updat 83:101286 PMID: 40769005
